Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL-39256
- Development stage
- Discontinued
- Lead developer
- Alcon
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
AL-39256 is a small molecule serotonin 5-HT2 receptor agonist developed by Alcon Research for the treatment of open-angle glaucoma and ocular hypertension. It was designed to lower intraocular pressure (IOP) by stimulating 5-HT2 receptors in the eye, a mechanism believed to enhance the uveoscleral outflow of aqueous humor. The compound was evaluated in a Phase 2 clinical trial (NCT00414414) to assess its safety and IOP-lowering efficacy compared to latanoprost, a standard prostaglandin analog, and a vehicle control. Clinical development of AL-39256 appears to have been terminated following the completion of this Phase 2 study in 2007.
02
Targets
Prostamide R (Prostamide receptor)
Beyond the preview
Go deeper on AL-39256.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL-39256.